Deconstruction of a nutlin: Dissecting the binding determinants of a potent protein-protein interaction inhibitor

ACS Medicinal Chemistry Letters

Volumn 4, Issue 7, 2013, Pages 660-665

  Fry, David C ^a   Wartchow, Charles ^a   Graves, Bradford ^a   Janson, Cheryl ^a   Lukacs, Christine ^a   Kammlott, Ursula ^a   Belunis, Charles ^a   Palme, Stefan ^b   Klein, Christian ^c   Vu, Binh ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c Roche Glycart AG   (Switzerland)

Author keywords

binding affinity; MDM2; Nutlin; p53; protein protein interaction inhibitor

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; NUTLIN; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; HETERONUCLEAR SINGLE QUANTUM COHERENCE; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

EID: 84880151043     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400062c     Document Type: Article

References (18)

1. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-1009
2. Fry, D. C. Targeting Protein-Protein Interactions for Drug Discovery. In Protein-Protein Interactions: Methods and Applications, 2 nd ed.; Fu, H.; Meyerkord, C., Eds.; Springer: New York, 2013; in press.
3. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1, 187-192
4. Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Fragment-based approaches in drug discovery and chemical biology Biochemistry 2012, 51, 4990-5003
5. Sperandio, O.; Reynes, C. H.; Camproux, A. C.; Villoutreix, B. O. Rationalizing the chemical space of protein-protein interaction inhibitors Drug Discovery Today 2010, 15, 220-229
6. Fry, D. C.; So, S.-S. Modulators of Protein-Protein Interactions: The Importance of Three-Dimensionality. In Protein-Protein Interactions in Drug Discovery; Doemling, A., Ed.; Wiley-VCH: Weinhelm, Germany, 2012; pp 55-62.
7. Bower, J. F.; Pannifer, A. Using fragment-based technologies to target protein-protein interactions Curr. Pharm. Des. 2012, 18, 4685-4696
8. Hajduk, P. J. Fragment-based drug design: how big is too big? J. Med. Chem. 2006, 49, 6972-6976
9. Barelier, S.; Pons, J.; Marcillat, O.; Lancelin, J.-M.; Krimm, I. Fragment-based deconstruction of Bcl-XL inhibitors J. Med. Chem. 2010, 53, 2577-2588
10. Van Molle, I.; Thomann, A.; Buckley, D. L.; So, E. C.; Lang, S.; Crews, C. M. Dissecting fragment-based lead discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α protein-protein interface Chem. Biol. 2012, 19, 1300-1312
11. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004, 303, 844-848
12. Tovar, C.; Graves, B.; Packman, K.; Higgins, B.; Xia, M.; Tardell, C.; Garrido, R.; Lee, E.; Kolinsky, K.; To, K.-H.; Linn, M.; Podlaski, F.; Wovkulich, P.; Vu, B.; Vassilev, L. MDM2 small molecule agonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models Cancer Res. 2013, 73, 2587-2597
13. Picksley, S. M.; Vojtesek, B.; Sparks, A.; Lane, D. P. Immunochemical analysis of the interaction of p53 with MDM2: fine mapping of the MDM2 binding site on p53 using synthetic peptides Oncogene 1994, 9, 2523-2529
14. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 1996, 274, 948-953
15. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
16. Schultes, S.; de Graaf, C.; Haaksma, E. E. J.; de Esch, I. J. P.; Leurs, R.; Kramer, O. Ligand efficiency as a guide in fragment hit selection and optimization Drug Discovery Today Technol. 2010, 7, e157-e162
17. Vu, B.; Wovkulich, P.; Pizzolato, G.; Lovey, A.; Ding, Q.; Jiang, N.; Liu, J.-J.; Zhao, C.; Glenn, K.; Wen, Y.; Tovar, C.; Packman, K.; Vassilev, L.; Graves, B. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development ACS Med. Chem. Lett. 2013, 4, 466-469
18. Williamson, M. P. Using chemical shift perturbation to characterise ligand binding Prog. Nucl. Magn. Reson. 2013, 73, 1-16